Vicapsys Life Sciences (Vicapsys Life Sciences) Additional Paid-In Capital : $14.34 Mil(As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Additional Paid-In Capital?

Vicapsys Life Sciences's quarterly additional paid-in capital increased from Mar. 2023 ($14.15 Mil) to Jun. 2023 ($14.34 Mil) and increased from Jun. 2023 ($14.34 Mil) to Sep. 2023 ($14.34 Mil).

Vicapsys Life Sciences's annual additional paid-in capital increased from Dec. 2020 ($13.42 Mil) to Dec. 2021 ($13.98 Mil) and increased from Dec. 2021 ($13.98 Mil) to Dec. 2022 ($14.14 Mil).

Vicapsys Life Sciences Additional Paid-In Capital Historical Data

The historical data trend for Vicapsys Life Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Additional Paid-In Capital Chart

Vicapsys Life Sciences Annual Data

Trend

Dec08

Dec09

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

3.14

13.40

13.42

13.98

14.14

Vicapsys Life Sciences Quarterly Data
	Jun10	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															14.07	14.14	14.15	14.34	14.34

Vicapsys Life Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Vicapsys Life Sciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vicapsys Life Sciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024

Website

https://www.vicapsys.com

Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

Executives

Moore Bobby M Jr	10 percent owner	4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen	10 percent owner	9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski	director	1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping	10 percent owner	2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees	director	C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser	director	641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier	director	1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon	director, 10 percent owner	8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus

ViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officer

By ACCESSWIRE ACCESSWIRE • 04-13-2022